WARNING: “Buffett Indicator” flashing for first time in 50 years

Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.

Take these 4 steps today to protect your retirement NOW

Matthew Mcilwain Biography and Net Worth

Director of Nautilus Biotechnology

Mr. Matthew Mcilwain is the Director of Nautilus Biotechnology.

What is Matthew S. Mcilwain's net worth?: The estimated net worth of Matthew S. Mcilwain is at least $590,784.48 as of August 26th, 2021. Mr. Mcilwain owns 335,673 shares of Nautilus Biotechnology stock worth more than $590,784 as of December 22nd. This net worth estimate does not reflect any other assets that Mr. Mcilwain may own. Learn More about Matthew S. Mcilwain's net worth.
How do I contact Matthew S. Mcilwain?: The corporate mailing address for Mr. Mcilwain and other Nautilus Biotechnology executives is 51 ASTOR PLACE 10TH FLOOR, NEW YORK NY, 10003. Nautilus Biotechnology can also be reached via phone at 206-333-2001 and via email at [email protected]. Learn More on Matthew S. Mcilwain's contact information.
Has Matthew S. Mcilwain been buying or selling shares of Nautilus Biotechnology?: Matthew S. Mcilwain has not been actively trading shares of Nautilus Biotechnology within the last three months. Most recently, on Monday, November 15th, Matthew S. Mcilwain bought 100,000 shares of Nautilus Biotechnology stock. The stock was acquired at an average cost of $5.30 per share, with a total value of $530,000.00. Learn More on Matthew S. Mcilwain's trading history.
Who are Nautilus Biotechnology's active insiders?: Nautilus Biotechnology's insider roster includes Matthew Mcilwain (Director), Anna Mowry (CFO), Matthew Murphy (General Counsel), Sujal Patel (CEO), and Matthew Posard (Director). Learn More on Nautilus Biotechnology's active insiders.
Are insiders buying or selling shares of Nautilus Biotechnology?: In the last year, Nautilus Biotechnology insiders bought shares 3 times. They purchased a total of 38,303 shares worth more than $108,316.27. In the last year, insiders at the sold shares 2 times. They sold a total of 82,031 shares worth more than $234,728.97. The most recent insider tranaction occured on September, 23rd when VP Mary E. Godwin sold 47,031 shares worth more than $134,978.97. Insiders at Nautilus Biotechnology own 40.5% of the company. Learn More about insider trades at Nautilus Biotechnology.
Information on this page was last updated on 9/23/2024.

Matthew S. Mcilwain Insider Trading History at Nautilus Biotechnology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/15/2021	Buy	100,000	$5.30	$530,000.00
8/26/2021	Buy	11,709	$7.71	$90,276.39	335,673
8/24/2021	Buy	13,568	$7.68	$104,202.24

Matthew S. Mcilwain Buying and Selling Activity at Nautilus Biotechnology

Nautilus Biotechnology Company Overview

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Today's Range

Now: $1.76

$1.74

$1.90

50 Day Range

MA: $2.41

$1.76

$2.96

2 Week Range

Now: $1.76

$1.74

$3.45

Volume

706,882 shs

Average Volume

86,477 shs

Market Capitalization

$220.99 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.14

From Behind the Markets | Ad

My research indicates there is only one investment that can meet AI's unprecedented demand for energy.

Click to get the name and ticker symbol